Gane E. Safety and Efficacy at 1 year after Switching from Tenofovir Disoproxil Fumurate to Tenofovir Alafenamide in Chronic HBV Patients with Risk Factors for TDF Use. PS-156.
Uniek eiwit verantwoordelijk voor membraanpotentiaal malaria
apr 2018 | Parasitaire infecties